AptarGroup, Inc. (ATR) Stock Price & How to Invest

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

The investment picture is one of a durable, defensive compounder rather than a fast grower. In Q1 2026 reported sales rose about 11% to roughly $983 million, but core (organic) sales were roughly flat, meaning acquisitions and currency drove most of the headline growth while underlying volume stalled. The second quarter was firmer: sales passed $1.03 billion, up about 6% year over year, and adjusted EPS of $1.42 beat the $1.35 consensus, the fourth straight quarter above estimates. Trailing twelve-month revenue is about $3.93 billion and net income about $363 million, with net earnings growth negative year over year (about -19%). The Pharma segment continues to face a planned multi-year step-down in emergency medicine dispensing sales (about $65 million expected in 2026), while injectables and other pharma lines grow. With a market capitalization near $8.0 billion, a trailing P/E around 23 (about 20 forward), and 30-plus consecutive years of dividend increases, Aptar reads as a low-volatility, quality-industrial holding.

Two pieces of news since summer bear on the story. In September 2026 Aptar disclosed that its Russian subsidiary, OOO Aptar Vladimir, will be placed under temporary external administration by decree of the Russian president; the company said it is evaluating its options and has not quantified a financial impact. On the pharma side, Aptar announced a collaboration with Massachusetts General Hospital on nose-to-brain drug delivery in September and CE marking for its LuerVax vaccine delivery device and spray divider in October. The shares were up about 2% year to date and down about 3% over one year as of October 16, 2026. UBS opened coverage at Neutral with a $135 target in October, while the nine-analyst mean target sits near $162.

Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. The planned decline in emergency medicine dispensing sales (about $65 million in 2026) is a known drag on the otherwise strong pharma segment, and analysts expect third-quarter EPS of about $1.47, roughly 9% below the year-ago quarter. Beauty and closures are exposed to consumer discretionary weakness, customer destocking, and input-cost swings. The Russian subsidiary placed under temporary state administration in September 2026 adds a write-down or loss-of-control risk that Aptar has not yet sized. Net debt of about $1.2 billion is moderate. At a P/E near 23 the stock is not cheap for a low-single-digit organic grower, and currency translation adds volatility given the company's large international footprint.

9 analysts publish price targets on ATR, averaging $162.00 against a $124.51 price as of October 2026, or +30.1%. The published targets run from $135.00 to $220.00, a moderate spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ATR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on AptarGroup, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. High-margin pharma drug delivery. The Pharma segment (nasal spray pumps, metered-dose inhaler valves, injectable elastomer components, and active packaging) is the profit engine and carries the highest margins of the three segments. The most optimistic published target, $220.00, assumes this works close to its best case.

The case against. Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. The most pessimistic target, $135.00, is roughly what ATR is worth if this bites instead.

Read the full bull and bear case on ATR, including what would have to change to break either one. Walnut is not an investment adviser.

No. AptarGroup, Inc. (ATR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AptarGroup, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.93B (Q2 2026 +6% y/y)
• Q2 2026 sales / adjusted EPS: ~$1.03B / $1.42 (vs $1.35 est.)
• Margins: Gross ~36%, operating ~12.5%, net ~9%
• Net income (TTM): ~$363M
• P/E: ~22.6x trailing, ~20x forward
• Market cap: ~$8.0B
• Dividend: $1.92/yr (~1.55% yield)
• Next earnings: Oct 29, 2026 (consensus EPS ~$1.47)

At $125 Aptar trades at about 23 times trailing and 20 times forward earnings, and about 11.5 times EBITDA, a premium to commodity packagers that rests on the pharma franchise and the dividend record. Analysts see 2026 EPS roughly flat at about $5.51 before a rebound to about $6.21 in 2027, so the multiple only looks reasonable if that recovery arrives. The key tension remains paying for quality while organic growth is near flat.

Other names that sit close to ATR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ATR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ATR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ATR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Aptar is a steady, pharma-anchored dispensing specialist whose investment case rests on its healthcare margins and long dividend record rather than rapid growth. Second-quarter 2026 results beat estimates, but the share price has gone roughly nowhere in 2026, and the next test is the third-quarter report on October 29, 2026.

Whether ATR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ATR a buy or a sell?, and where the stock could go from here in the ATR stock forecast.

For income investors, whether ATR pays a dividend and how the payout looks is covered in does ATR pay a dividend? And to weigh ATR against a peer, read the full side-by-side comparisons: ATR vs AG and ATR vs SLGN.